View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsSpectrum Pharmaceuticals 향후 성장Future 기준 점검 5/6현재 Spectrum Pharmaceuticals 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.핵심 정보67.3%이익 성장률75.36%EPS 성장률Biotechs 이익 성장24.0%매출 성장률35.5%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트25 Jul 2023최근 향후 성장 업데이트Breakeven Date Change • May 11Forecast breakeven date moved forward to 2024The 5 analysts covering Spectrum Pharmaceuticals previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 57% to 2023. The company is expected to make a profit of US$2.95m in 2024. Average annual earnings growth of 65% is required to achieve expected profit on schedule.공시 • Feb 01Spectrum Pharmaceuticals, Inc. Provides Sales Guidance for the Quarter Ended December 31, 2022Spectrum Pharmaceuticals, Inc. provided sales guidance for the quarter ended December 31, 2022. Preliminary net sales for the quarter ended December 31, 2022 is expected to be approximately $10 million.Breakeven Date Change • Dec 31Forecast to breakeven in 2025The 4 analysts covering Spectrum Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$26.8m in 2025. Average annual earnings growth of 57% is required to achieve expected profit on schedule.Breakeven Date Change • Sep 24No longer forecast to breakevenThe 5 analysts covering Spectrum Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$31.1m in 2024. New consensus forecast suggests the company will make a loss of US$12.3m in 2024.Breakeven Date Change • May 16Forecast to breakeven in 2024The 5 analysts covering Spectrum Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$46.6m in 2024. Average annual earnings growth of 65% is required to achieve expected profit on schedule.Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 5 analysts covering Spectrum Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$52.8m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.모든 업데이트 보기Recent updates공시 • Aug 03Spectrum Pharmaceuticals, Inc.(NasdaqCM:SPPI) dropped from NASDAQ Composite IndexSpectrum Pharmaceuticals, Inc. has been dropped from Nasdaq Composite Index.공시 • May 18Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RequirementSpectrum Pharmaceuticals, Inc. announced that on May 16, 2023, the Company received a written notification from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (Nasdaq) that the Company has regained compliance with the minimum bid price requirement set in Nasdaq Listing Rule 5550(a)(2). The Company previously received notification from the Staff on November 1, 2022, that its common stock failed to maintain a minimum bid price of $1.00 or more over the previous 30 consecutive business days, as required by the Nasdaq Listing Rules. Since then, the Staff has determined that for the 10 consecutive business days from May 2 to May 15, 2023, the closing bid price of Spectrum’s common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed.Breakeven Date Change • May 11Forecast breakeven date moved forward to 2024The 5 analysts covering Spectrum Pharmaceuticals previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 57% to 2023. The company is expected to make a profit of US$2.95m in 2024. Average annual earnings growth of 65% is required to achieve expected profit on schedule.공시 • Feb 09Spectrum Pharmaceuticals, Inc. Receives Permanent J-Code for ROLVEDON Injection (J1449) from U.S. Centers for Medicare & Medicaid ServicesSpectrum Pharmaceuticals, Inc. announced that a permanent J-code, J1449, has been issued for ROLVEDON (eflapegrastim-xnst) Injection by the U.S. Centers for Medicare & Medicaid Services (CMS) effective as of April 1, 2023. J-codes are permanent reimbursement codes used by commercial insurance plans, Medicare, Medicare Advantage, and other government payers for Medicare Part B drugs like ROLVEDON that are administered by a physician. Claims submission and documentation are simplified with a permanent J-code, facilitating and streamlining the billing and reimbursement process. The permanent J-code for ROLVEDON, J1449 (Injection, eflapegrastim-xnst, 0.1 mg), will take effect April 1, 2023.공시 • Feb 01Spectrum Pharmaceuticals, Inc. Provides Sales Guidance for the Quarter Ended December 31, 2022Spectrum Pharmaceuticals, Inc. provided sales guidance for the quarter ended December 31, 2022. Preliminary net sales for the quarter ended December 31, 2022 is expected to be approximately $10 million.공시 • Jan 05Spectrum Pharmaceuticals Announces Executive ChangesSpectrum Pharmaceuticals, Inc. announced that Francois J. Lebel, M.D., Executive Vice President and Chief Medical Officer, will step down from his role to pursue other opportunities, effective immediately. The company’s clinical development function will be led by Dr. Shanta Chawla, Vice President, Clinical Development, also effective immediately. Dr. Chawla was the principal physician on the ROLVEDON™ (eflapegrastim-xnst) injection Phase 3 program and was instrumental in successfully navigating the BLA submission that resulted in the drug’s approval. Dr. Lebel will serve as a consultant to Spectrum through March 2023 to facilitate a seamless transition.Breakeven Date Change • Dec 31Forecast to breakeven in 2025The 4 analysts covering Spectrum Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$26.8m in 2025. Average annual earnings growth of 57% is required to achieve expected profit on schedule.Breakeven Date Change • Sep 24No longer forecast to breakevenThe 5 analysts covering Spectrum Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$31.1m in 2024. New consensus forecast suggests the company will make a loss of US$12.3m in 2024.Breakeven Date Change • May 16Forecast to breakeven in 2024The 5 analysts covering Spectrum Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$46.6m in 2024. Average annual earnings growth of 65% is required to achieve expected profit on schedule.Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 5 analysts covering Spectrum Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$52.8m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.Breakeven Date Change • Aug 07No longer forecast to breakevenThe 6 analysts covering Spectrum Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$4.50m in 2023. New consensus forecast suggests the company will make a loss of US$21.5m in 2023.Board Change • Jul 31High number of new directorsIndependent Director Nora Brennan was the last director to join the board, commencing their role in 2020.Breakeven Date Change • May 19Forecast breakeven pushed back to 2024The 6 analysts covering Spectrum Pharmaceuticals previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of US$79.4m in 2024. Average annual earnings growth of 68% is required to achieve expected profit on schedule.Is New 90 Day High Low • Mar 05New 90-day low: €2.64The company is down 34% from its price of €4.02 on 04 December 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €13.33 per share.Is New 90 Day High Low • Dec 31New 90-day low: €2.78The company is down 21% from its price of €3.50 on 02 October 2020. The German market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €10.83 per share.Is New 90 Day High Low • Dec 15New 90-day high: €4.04The company is up 15% from its price of €3.52 on 16 September 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.15 per share.Is New 90 Day High Low • Nov 10New 90-day low: €2.84The company is down 13% from its price of €3.28 on 11 August 2020. The German market is flat over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Biotechs industry, which is also down 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.99 per share.Is New 90 Day High Low • Sep 19New 90-day high: €3.84The company is up 39% from its price of €2.76 on 19 June 2020. The German market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €28.74 per share.이익 및 매출 성장 예측DB:NTR - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20252019736141412/31/2024127141836512/31/202373-18-21233/31/202326-68-88-88N/A12/31/202210-78-97-97N/A9/30/2022N/A-106-102-102N/A6/30/2022N/A-117-109-109N/A3/31/2022N/A-138-115-115N/A12/31/2021N/A-158-120-119N/A9/30/2021N/A-169-121-122N/A6/30/2021N/A-184-127-125N/A3/31/2021N/A-166-127-123N/A12/31/2020N/A-171-127-122N/A9/30/2020N/A-162-127-120N/A6/30/2020N/A-140-131-119N/A3/31/2020N/A-136-138-128N/A12/31/2019N/A-135-144-135N/A9/30/2019N/A-148-127-116N/A6/30/2019N/A-191-103-100N/A3/31/2019N/A-147-79-76N/A12/31/2018N/A-127-65-62N/A9/30/201829-102-63-63N/A6/30/201865-51-59-59N/A3/31/201899-87-46-45N/A12/31/2017N/A-101-39-39N/A9/30/2017135-81-30-29N/A6/30/2017132-81-36-36N/A3/31/2017132-84-54-54N/A12/31/2016146-70N/A-40N/A9/30/2016162-55N/A-34N/A6/30/2016157-56N/A-30N/A3/31/2016168-35N/A5N/A12/31/2015163-53N/A7N/A9/30/2015164-50N/A15N/A6/30/2015183-42N/A34N/A3/31/2015185-44N/A31N/A12/31/2014187-46N/A-4N/A9/30/2014176-82N/A-7N/A6/30/2014171-78N/A-30N/A3/31/2014157-84N/A-64N/A12/31/2013156-62N/A-2N/A9/30/2013184-15N/A-2N/A6/30/201321114N/A30N/A3/31/201324742N/A67N/A12/31/201226894N/A72N/A9/30/201225195N/A75N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: NTR 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(0.2%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: NTR (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: NTR 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: NTR 의 수익(연간 35.5%)이 German 시장(연간 6.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: NTR 의 수익(연간 35.5%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: NTR의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/08/01 06:13종가2023/07/31 00:00수익2023/03/31연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Spectrum Pharmaceuticals, Inc.는 9명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관David BuckB. Riley Securities, Inc.Alethia YoungCantor Fitzgerald & Co.Reni BenjaminCitizens JMP Securities, LLC6명의 분석가 더 보기
Breakeven Date Change • May 11Forecast breakeven date moved forward to 2024The 5 analysts covering Spectrum Pharmaceuticals previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 57% to 2023. The company is expected to make a profit of US$2.95m in 2024. Average annual earnings growth of 65% is required to achieve expected profit on schedule.
공시 • Feb 01Spectrum Pharmaceuticals, Inc. Provides Sales Guidance for the Quarter Ended December 31, 2022Spectrum Pharmaceuticals, Inc. provided sales guidance for the quarter ended December 31, 2022. Preliminary net sales for the quarter ended December 31, 2022 is expected to be approximately $10 million.
Breakeven Date Change • Dec 31Forecast to breakeven in 2025The 4 analysts covering Spectrum Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$26.8m in 2025. Average annual earnings growth of 57% is required to achieve expected profit on schedule.
Breakeven Date Change • Sep 24No longer forecast to breakevenThe 5 analysts covering Spectrum Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$31.1m in 2024. New consensus forecast suggests the company will make a loss of US$12.3m in 2024.
Breakeven Date Change • May 16Forecast to breakeven in 2024The 5 analysts covering Spectrum Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$46.6m in 2024. Average annual earnings growth of 65% is required to achieve expected profit on schedule.
Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 5 analysts covering Spectrum Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$52.8m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
공시 • Aug 03Spectrum Pharmaceuticals, Inc.(NasdaqCM:SPPI) dropped from NASDAQ Composite IndexSpectrum Pharmaceuticals, Inc. has been dropped from Nasdaq Composite Index.
공시 • May 18Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RequirementSpectrum Pharmaceuticals, Inc. announced that on May 16, 2023, the Company received a written notification from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (Nasdaq) that the Company has regained compliance with the minimum bid price requirement set in Nasdaq Listing Rule 5550(a)(2). The Company previously received notification from the Staff on November 1, 2022, that its common stock failed to maintain a minimum bid price of $1.00 or more over the previous 30 consecutive business days, as required by the Nasdaq Listing Rules. Since then, the Staff has determined that for the 10 consecutive business days from May 2 to May 15, 2023, the closing bid price of Spectrum’s common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed.
Breakeven Date Change • May 11Forecast breakeven date moved forward to 2024The 5 analysts covering Spectrum Pharmaceuticals previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 57% to 2023. The company is expected to make a profit of US$2.95m in 2024. Average annual earnings growth of 65% is required to achieve expected profit on schedule.
공시 • Feb 09Spectrum Pharmaceuticals, Inc. Receives Permanent J-Code for ROLVEDON Injection (J1449) from U.S. Centers for Medicare & Medicaid ServicesSpectrum Pharmaceuticals, Inc. announced that a permanent J-code, J1449, has been issued for ROLVEDON (eflapegrastim-xnst) Injection by the U.S. Centers for Medicare & Medicaid Services (CMS) effective as of April 1, 2023. J-codes are permanent reimbursement codes used by commercial insurance plans, Medicare, Medicare Advantage, and other government payers for Medicare Part B drugs like ROLVEDON that are administered by a physician. Claims submission and documentation are simplified with a permanent J-code, facilitating and streamlining the billing and reimbursement process. The permanent J-code for ROLVEDON, J1449 (Injection, eflapegrastim-xnst, 0.1 mg), will take effect April 1, 2023.
공시 • Feb 01Spectrum Pharmaceuticals, Inc. Provides Sales Guidance for the Quarter Ended December 31, 2022Spectrum Pharmaceuticals, Inc. provided sales guidance for the quarter ended December 31, 2022. Preliminary net sales for the quarter ended December 31, 2022 is expected to be approximately $10 million.
공시 • Jan 05Spectrum Pharmaceuticals Announces Executive ChangesSpectrum Pharmaceuticals, Inc. announced that Francois J. Lebel, M.D., Executive Vice President and Chief Medical Officer, will step down from his role to pursue other opportunities, effective immediately. The company’s clinical development function will be led by Dr. Shanta Chawla, Vice President, Clinical Development, also effective immediately. Dr. Chawla was the principal physician on the ROLVEDON™ (eflapegrastim-xnst) injection Phase 3 program and was instrumental in successfully navigating the BLA submission that resulted in the drug’s approval. Dr. Lebel will serve as a consultant to Spectrum through March 2023 to facilitate a seamless transition.
Breakeven Date Change • Dec 31Forecast to breakeven in 2025The 4 analysts covering Spectrum Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$26.8m in 2025. Average annual earnings growth of 57% is required to achieve expected profit on schedule.
Breakeven Date Change • Sep 24No longer forecast to breakevenThe 5 analysts covering Spectrum Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$31.1m in 2024. New consensus forecast suggests the company will make a loss of US$12.3m in 2024.
Breakeven Date Change • May 16Forecast to breakeven in 2024The 5 analysts covering Spectrum Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$46.6m in 2024. Average annual earnings growth of 65% is required to achieve expected profit on schedule.
Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 5 analysts covering Spectrum Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$52.8m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
Breakeven Date Change • Aug 07No longer forecast to breakevenThe 6 analysts covering Spectrum Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$4.50m in 2023. New consensus forecast suggests the company will make a loss of US$21.5m in 2023.
Board Change • Jul 31High number of new directorsIndependent Director Nora Brennan was the last director to join the board, commencing their role in 2020.
Breakeven Date Change • May 19Forecast breakeven pushed back to 2024The 6 analysts covering Spectrum Pharmaceuticals previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of US$79.4m in 2024. Average annual earnings growth of 68% is required to achieve expected profit on schedule.
Is New 90 Day High Low • Mar 05New 90-day low: €2.64The company is down 34% from its price of €4.02 on 04 December 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €13.33 per share.
Is New 90 Day High Low • Dec 31New 90-day low: €2.78The company is down 21% from its price of €3.50 on 02 October 2020. The German market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €10.83 per share.
Is New 90 Day High Low • Dec 15New 90-day high: €4.04The company is up 15% from its price of €3.52 on 16 September 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.15 per share.
Is New 90 Day High Low • Nov 10New 90-day low: €2.84The company is down 13% from its price of €3.28 on 11 August 2020. The German market is flat over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Biotechs industry, which is also down 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.99 per share.
Is New 90 Day High Low • Sep 19New 90-day high: €3.84The company is up 39% from its price of €2.76 on 19 June 2020. The German market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €28.74 per share.